According to the Complaint, Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on using complement biology to bring innovative and accessible therapies to patients with rare diseases.

This action stems from a proposed transaction announced on October 10, 2019, pursuant to which Ra Pharmaceuticals will be acquired by UCB S.A.

On October 9, 2019, Ra Pharmaceuticals’ Board of Directors caused the Company to enter into an agreement and plan of merger with UCB. Pursuant to the terms of the Merger Agreement, Ra Pharmaceuticals’ stockholders will receive $48.00 in cash for each share of Ra Pharmaceuticals common stock they own.

On November 1, 2019, Defendants filed a Proxy Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.

This case was voluntarily dismissed on February 24, 2021.